Boothbay Fund Management, LLC Astria Therapeutics, Inc. Transaction History

Boothbay Fund Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$6.99 - $16.69 $255,065 - $609,018	-36,490 Reduced 58.91%	25,453 $358,000
Q3 2023 Nov 14, 2023	SELL	$6.89 - $9.86 $184,073 - $263,419	-26,716 Reduced 30.13%	61,943 $462,000
Q2 2023 Aug 14, 2023	SELL	$8.33 - $13.72 $432,860 - $712,946	-51,964 Reduced 36.95%	88,659 $738,000
Q1 2023 May 15, 2023	BUY	$11.2 - $15.79 $378,571 - $533,717	33,801 Added 31.64%	140,623 $1.87 Million
Q4 2022 Feb 14, 2023	BUY	$7.44 - $14.89 $38,710 - $77,472	5,203 Added 5.12%	106,822 $1.59 Million
Q3 2022 Nov 14, 2022	BUY	$2.97 - $10.34 $76,762 - $267,247	25,846 Added 34.11%	101,619 $919,000
Q2 2022 Aug 15, 2022	BUY	$2.46 - $6.96 $186,401 - $527,380	75,773 New	75,773 $227,000

107

48.6M

48K

9.3K

Ticker ATXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,178,000
Market Cap $146M
Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.